Medical News
Real-world Comparative Effectiveness of ARNI vs. ACEi/ARB in...
Clin Res Cardiol.
In this nationwide real-world study including a population of patients with HF with reduced or mildly reduced EF,...
01 Dec 2022
Impact of Diabetes on 10‐Year Outcomes Following STEMI
J Am Heart Assoc.
Patients with ST‐segment–elevation myocardial infarction who had diabetes had worse clinical outcome at 10 years...
30 Nov 2022
Effects of LA Function on PAP in AMI, Hypertrophic and Dilat...
BMC Cardiovasc Disord.
The left atrial (LA) function in HCM and DCM and LV fibrosis in DCM correlated with PASP independent of E/e′ and LA...
29 Nov 2022
Risk of Mortality and Other Adverse Outcomes from MI in Canc...
Int. J. Clin. Oncol
This meta-analysis shows that cancer increases the risk of all-cause mortality, recurrent MI, and major bleeding in...
29 Nov 2022
eCMEs
Key Trials
Efficacy of Triple vs Double Oral Therapy in Newly Diagnosed PAH Patients
Although both the treatment regimens - initial triple and double therapy significantly reduced the pulmonary vascular resistance (PVR) in newly...
Treatment with Sacubitril/valsartan Associated with Improved Hemodynamic Status in Patients with HFrEF
According to the study, HFrEF patients treated with sacubitril/valsartan had improved hemodynamic status, as assessed by the changes in the...
Global Longitudinal Strain: A Robust and Independent Prognostic Indicator in Patients with HFimpEF
Global longitudinal strain is a strong and independent predictor for future HF events and deteriorating cardiac function in patients with HFimpEF....
ARNI Superior to ACEI/ARB in reducing CV Outcomes in Patients with Acute Myocardial Infarction
The study demonstrated ARNI to be superior to ACE inhibitor or ARB for reducing long-term adverse cardiovascular outcomes in patients with acute MI...
Slide Library
Medical Management Strategy of CTEPH: Role of Riociguat
Riociguat, a stimulator of soluble guanylate cyclase, has been globally approved for the treatment of PAH and inoperable CTEPH and persistent/...
Macitentan: 1st ERA Proven to Reduce Morbidity and Mortality in PAH
Macitentan is an orally active, potent, tissue targeting ERA that is indicated for the treatment of pulmonary arterial hypertension (PAH). It is the...
Chronic Thromboembolic Pulmonary Hypertension
Chronic thromboembolic pulmonary hypertension (CTEPH) is the presence of mean pulmonary artery pressure (mPAP) ≥ 25 mmHg following an episode of...
Diabetic Dyslipidemia
Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...
Our Publications
CARLOC-I (Carvedilol +Ivabradine) Monograph
Carvedilol/ivabradine have a proven chemical-pharmaceutical quality and are considered an approvable fixed-dose combination. Both carvedilol and...
Rivazest (Rivaroxaban) Monograph
Rivaroxaban is a potent, selective, orally active direct inhibitor of the activated serine protease Factor X (FXa), which plays a central role in...
Telyse (Tenecteplase) Monograph
In the management of STEMI in India, pharmacoinvasive strategy involving thrombolytics is the preferred therapy in cases of delays in primary PCI....
Mexiletine FAQ Booklet
Mexiletine is a class 1B antiarrhythmic agent, which blocks the sodium channels and is indicated in suppression of ventricular arrhythmias. The...
Patient Education
Understanding Angioplasty
Angioplasty is a life-saving procedure to open up blocked or narrowed blood vessels. This document gives a brief idea about the procedure.
Understanding Obesity
This document explains what is obesity, what is the impact of obesity on overall health and what are the benefits of weight loss.
Hypertension
Know more about the risk factors, associated ill-effects and tips for management of hypertension or high blood pressure.
.jpg)
Poll
What percent of your patients who need oral anticoagulation, receive warfarin?
<20%
20-40%
40-50%
50-70%
70-80%
Almost all
Total votes: 28